Immune Fog May Flag Lung Cancer Risk Years Before Tumors Form

A newly identified biological signature known as “immune fog” could help doctors detect lung cancer risk years before malignant tumors actually form, according to groundbreaking scientific research published in the journal Nature.

The study, led by researchers including Samuel Gamble and detailed in the October 2026 publication, sheds new light on the earliest stages of lung cancer development. By analyzing blood and tissue samples from participants in long-running lung cancer surveillance and screening studies, alongside laboratory research in mice, investigators uncovered crucial details about how precancerous lesions evolve into full-fledged tumors.

The Role of Regulatory T Cells in Early Lung Cancer

At the center of the discovery is an accumulation of regulatory T cells, commonly referred to as Tregs. These specialized immune system cells gradually built up months or even years before cancer became clinically detectable in patients.

In healthy biological responses, regulatory T cells help keep the immune system in check and prevent autoimmune reactions. However, researchers found that in the context of developing lung cancer, these cells create an immunosuppressive environment—described as an immune fog—that allows precancerous cells to evade detection and continue growing unchecked.

Promising Results from Prototype Tests and Animal Models

During the investigation, scientists successfully tracked this accumulating immune signal using prototype blood tests, suggesting a potential pathway for future early-interception strategies in high-risk patients.

Furthermore, experiments involving mice demonstrated that administering a drug designed to reverse this immune suppression cut the proportion of mice developing lung tumors in half. Even more significantly, the treatment completely prevented the formation of all large tumors in the test subjects.

While further clinical development and human trials are necessary before these prototype tests and treatments can be deployed in routine healthcare settings, the findings mark an important step forward in lung cancer interception and early medical screening.